α-Klotho is a longevity-related
protein. Its deficiency shortens lifespan with prominent senescent phenotypes, including
muscle atrophy and weakness in mice. α-Klotho has two forms: membrane α-Klotho and circulating α-Klotho (c-α-Klotho). Loss of membrane α-Klotho impairs a phosphaturic effect, thereby accelerating
phosphate-induced aging. However, the mechanisms of senescence on c-α-Klotho loss remain largely unknown. Herein, with the aging of wild-type mice, c-α-Klotho declined, whereas Smad2, an intracellular
transforming growth factor (TGF)-β effector, became activated in skeletal muscle. Moreover, c-α-Klotho suppressed muscle-wasting TGF-β molecules, including
myostatin, growth and differentiation
factor 11,
activin, and TGF-β1, through binding to
ligands as well as type I and type II
serine/threonine kinase receptors. Indeed, c-α-Klotho reversed impaired in vitro myogenesis caused by these TGF-βs.
Oral administration of
Ki26894, a small-molecule inhibitor of type I receptors for these TGF-βs, restored
muscle atrophy and weakness in α-Klotho (-/-) mice and in elderly wild-type mice by suppression of activated Smad2 and up-regulated Cdkn1a (p21) transcript, a target of phosphorylated Smad2.
Ki26894 also induced the slow to fast myofiber switch. These findings show c-α-Klotho's potential as a circulating inhibitor counteracting TGF-β-induced
sarcopenia. These data highlight the potential of a novel
therapy involving TGF-β blockade to prevent
sarcopenia.